Those who survive breast cancer still live under the uneasy threat of recurrence. But a recent biomarker discovery might take the mystery and guesswork out of that threat. Researchers from Virginia Commonwealth University Massey Cancer Center have discovered a new biomarker related to the body's immune system that can predict breast cancer patients' risk of recurrence. The researchers found that a specific, five-gene signature related to tumor infiltrating immune cells can accurately predict relapse-free survival. The signature predicted relapse with more than 85 percent accuracy. Release | UPI story